Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are under 50 years old at the time of joining the trial.
• People who have no more than 4 nodules (small lumps) in each lung that are suspected to be cancer that has spread, where at least one nodule is 3mm or larger and all nodules are 3cm or smaller — eligibility must be confirmed through a central imaging review process run by the trial.
• People whose lung nodules are considered removable by surgery, as determined by the surgeon at the treating institution.
• People who have been diagnosed with osteosarcoma (a type of bone cancer), confirmed by a tissue sample.
• People whose cancer had spread to the lungs either at the time of their first diagnosis, or at the time of their first relapse after completing treatment for cancer that was originally confined to one area.
• People newly diagnosed with osteosarcoma who have already had their main tumour surgically removed, or for whom that surgery is planned to happen at the same time as the lung surgery.
• People newly diagnosed with osteosarcoma who are currently receiving, or have recently completed (within the past 60 days), standard chemotherapy for osteosarcoma (such as regimens containing cisplatin-doxorubicin or ifosfamide) — dose adjustments due to side effects do not prevent participation.
• People joining the trial at the time of their first relapse who have completed standard chemotherapy for their original osteosarcoma diagnosis — dose adjustments due to side effects do not prevent participation.

Who may not be able to join:

• People whose primary (main) tumour cannot be surgically removed.
• People whose lung nodules would require removal of an entire lobe or an entire lung, or whose nodules are located in a central airway area of the lung (confirm with trial site for exact definition).
• People who have cancer nodules in the chest wall or the area between the lungs (mediastinum), or who have a significant build-up of fluid around the lungs.
• People whose cancer — either at the primary site or in the lungs — has continued to grow and spread during their initial treatment (note: small measurement variations in nodule size during pre-surgical treatment are expected and do not automatically lead to exclusion unless the treating team determines it is true disease progression).
• People who have cancer that has spread to areas outside the lungs.
• People who have already had lung surgery to remove cancer that had spread to the lungs before joining this trial.
• People (or their parents or legal guardians, where applicable) who are not able or willing to sign a written consent form.
• People whose participation would not meet the requirements of the relevant institutional review processes, the FDA, or the National Cancer Institute.

Important: Always verify eligibility with the trial site directly before applying.